No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
www.bms.comNo one on the platform currently holds CELG-RI.
No tracked institution reports a position in CELG-RI as of their last filing.
No one on the platform has traded CELG-RI yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.6% | 18.6% | 19.5% | — | — | — |
| Rev. Growth % | 17.5% | 18.7% | ||||
| Profit Margin % | 26.5% | 22.1% | 23.9% | |||
| Free Cash Flow Margin % | 31.7% | 32.3% | 32.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $49.6B | +3.3% | $6.93 | $6.93–$6.93 | — | 1 |
| 2027 | $48.1B | -3.0% | $6.55 | $6.55–$6.55 | — | 1 |
| 2028 | $41.9B | -12.8% | $5.63 | $5.63–$5.63 | — | 1 |
| 2029 | $38.0B | -9.5% | $5.08 | $5.08–$5.08 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.60 | $2.04 | +27.5% |
| 2026-04-30 | $1.42 | $1.58 | +11.3% |
| 2026-02-05 | $1.23 | $1.26 | +2.4% |
| 2025-10-30 | $1.52 | $1.63 | +7.2% |
| 2025-07-31 | $1.09 | $1.46 | +33.9% |
| 2025-04-24 | $1.49 | $1.80 | +20.8% |
| 2025-02-06 | $1.46 | $1.67 | +14.4% |
| 2024-10-31 | $1.49 |
| $1.80 |
| +20.8% |
| $100.4B |
| — |
| HCAHCA Healthcare, Inc. | $423.96 | -0.36% | $91.8B | — |
| MCKMcKesson Corporation | $895.12 | -1.74% | $104.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.